Tag Archive for: calliditas

Monday, 28th February is #RareDiseaseDay

We are proud to work with amazing companies focused on developing new treatments for rare diseases, generating change for the 300 million people worldwide

FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy

TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g1 TARPEYO (developed under the project name NEFECON) is the first and only FDA- approved treatment that was specifically designed for […]

Optimum Video Q&A: Getting to know Renee Aguiar-Lucander

Since taking over as CEO of Calliditas Therapeutics in 2017, Renee Aguiar-Lucander has taken the biotech through an IPO in Stockholm and commenced a pivotal phase 3 trial plus major licensing deals and a secondary fund raise.  She has established a US presence, made transformational regulatory milestones, and this month completed a successful upsized US […]